November 2016 Br J Cardiol 2016;23:138–40 doi:10.5837/bjc.2016.037
JJ Coughlan, Conor Hickie, Barbara Gorna, Ross Murphy, Peter Crean
Introduction Coronary artery disease remains one of the leading causes of death in Ireland,1 the UK,2 and worldwide. Despite advances in management, it is a major source of morbidity and mortality in our healthcare system. Numerous trials (PROVE-IT,3 ISIS-1,4 ISIS-2,5 ISIS-3,6 ISIS-4,7 AIRE,8 CAPRICORN9) have established the prognostic benefits associated with adequate secondary prevention post ST-elevation myocardial infarction (STEMI). National Institute for Health and Care Excellence (NICE) guidelines10 recommend all patients discharged post-STEMI should be offered treatment with an angiotensin-converting enzyme inhibitor (ACEi), beta bloc
You need to be a member to print this page.
Find out more about our membership benefits
You need to be a member to download PDF's.
Find out more about our membership benefits